Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzeon immunological benefits in HIV
NCT00461266Phase 4Withdrawn
- Sponsor
- Roche
- Start
- Apr 2007
- Primary completion
- Jan 2008
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enfuvirtide in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Roche. Primary endpoint: Mean change in CD4 cell count from baseline at 24 weeks. Planned start Apr 2007; status: withdrawn.
02
Drugs
enfuvirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00461266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00461266.